Pubblicazioni scientifiche sui diagnostici non invasivi BioPredictive
Studi sottoposti a revisione paritaria che convalidano i diagnostici ematici BioPredictive per le malattie del fegato — dalle coorti di sviluppo pionieristiche alle meta-analisi a lungo termine.
27/435
Risultati per
“HDL-C, high-density lipoprotein cholesterol”
-
Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.
…chronic hyper-low-density lipoprotein and hypo-high-density lipoprotein cholesterolemia induces…
-
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts. Key publication
### Background Studies have demonstrated that coronary artery calcification on one hand and…
-
Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.
### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…
-
PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.
…allele carriers than that in C allele homozygote carriers (70.3 vs…
-
Silymarin in non alcoholic fatty liver disease.
### Aim This study was undertaken to evaluate the hepatic effects of silybum…
-
An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.
…BMI, HbA1c, triglycerides, and high-density lipoprotein-cholesterol) revealed significantly lower 15…
-
The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.
### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…
-
Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.
…14.8; p = 0.001), cholesterol (236.4 ± 54.8 vs 204…
-
Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…
-
Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography.
### Objective Patients with short bowel syndrome (SBS) receiving long-term parenteral nutrition…
-
The use of enzyme results for liver fibrosis evaluation neccessitates standardization.
-
Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.
…hyperlipidaemic patients appears to be high (3%, 30% and 7%, respectively). Biomarkers…
-
The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. Key publication
### Background/Aims The aim was to identify a panel of biomarkers (AshTest…
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication
In patients with non-alcoholic fatty liver disease (NAFLD) with or without…
-
Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication
…A1, the main transporter of HDL-cholesterol, to identify the early spread…
-
Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study.
…We used proteomics to identify novel fibrosis biomarkers in hepatitis C patients…
-
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.
### Background And Aim Significant hepatic fibrosis is prognostic of liver morbidity and…
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Key publication
…to those in chronic hepatitis C (CHC), B (CHB), and alcoholic liver…
-
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
…virological response in chronic hepatitis C (CHC) is interferon-gamma-inducible protein…
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review
-
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
…To date, no studies have assessed the efficacy and safety of high…
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…
-
Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis. Key publication
### Background No prospective diagnostic studies have directly compared widespread non-invasive liver…
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
…diagnosis in patients with a high clinical suspicion of ALD in whom…
-
Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C — Rapport de recommandations 2014 Key publication
Mostra l'elenco completo dei risultati. La pagina è renderizzata sul server e non è paginata.